BioNTech's Long Road to 106 Euros: ASCO Data, a $1B Buyback, and Six Make-or-Break Readouts
14.06.2026 - 03:25:17 | boerse-global.de
BioNTech's transformation from a pandemic winner to a focused oncology player will face its next test on August 4, when the company reports second-quarter earnings. The stock closed the previous week at €78.10, a level that leaves a yawning 36% gap to the analysts' average target of €106.18. That disconnect reflects a market unconvinced that the ongoing pivot will pay off soon.
The company started a $1 billion share buyback on June 8, scheduled to run until May 2027. This program is a deliberate vote of confidence from a management team sitting on a liquidity hoard of €16.8 billion. That war chest buys time and flexibility while BioNTech burns cash on an expensive corporate overhaul. In the first quarter, revenue from its legacy Covid vaccine business fell to just €118.1 million, while the net loss widened to €531.9 million.
At the ASCO conference in Chicago in late May and early June, BioNTech presented fresh clinical data that strengthened the rationale for that pivot. The bispecific antibody Pumitamig (BNT327) showed promising anti-tumor activity in combination with chemotherapy for lung cancer in the ROSETTA study. Gotistobart (BNT311) demonstrated durable survival benefits in heavily pretreated platinum-resistant ovarian cancer. Both drugs are crucial pillars of the late-stage pipeline, though the key Phase 3 trials remain ongoing.
Should investors sell immediately? Or is it worth buying BioNTech?
Despite these encouraging signals, the market response was muted. The stock has lost roughly 5% since the start of 2026 and nearly 14% over the past twelve months. Investor caution is compounded by planned departures of the company's co-founders, creating leadership uncertainty at a critical juncture. The operational restructuring is equally stark: in May alone, BioNTech and Takeda together cut more than 6,300 positions, underscoring the sector-wide efficiency drive.
Efficiency, however, can only take the company so far. The real value lies in the pipeline, which spans more than 25 oncology studies. By the end of 2026, management has flagged six major data updates from late-stage trials. Overall, the company expects seven important readouts this year, adding to the 15 Phase 3 studies now underway. These milestones will determine whether BioNTech can secure the first commercial oncology approvals and begin to replace the shrinking vaccine revenue.
The $1 billion buyback provides a near-term floor, but it cannot substitute for clinical success. The cash pile ensures that BioNTech can fund its R&D without immediate financial distress, even as the Covid vaccine business fades. The 200-day moving average, currently at €85.61, sits about 9% above the current share price, further reflecting technical weakness.
The second-quarter earnings on August 4 will be the next near-term catalyst, offering a progress report on both the restructuring and the pipeline execution. For investors, the arithmetic is simple: if the six late-stage readouts deliver convincing results, the 36% upside to the analyst target becomes plausible. If not, the shares may remain in the doldrums. BioNTech is playing a long game, and the market is demanding evidence before it rewards the bet.
Ad
BioNTech Stock: New Analysis - 14 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
